The lab-grown meat developer has picked up $47m in its series A round thanks to commitments from investors including Section 32 and Agronomics.

Poly Group unit Poly Huixin Fund Investment Management was among the new investors for the industrial cybersecurity software provider.

Qualcomm Ventures has returned to back the e-commerce platform developer’s series D round after co-leading its previous round late last year.

Lilly Asia Ventures co-led a $61.4m round for the antibody drug developer that will fund development of breast and gastric cancer drug candidates.

Peking University-backed Yanchuang Capital co-led a series A round for Innoforce Pharmaceuticals that will support the construction of manufacturing facilities.

Exor Seeds has led the $59.5m equity portion of the real estate platform developer's series C round, which included $179m in facility financing.

Cash Capital has participated in a $70m series B round for Shanghai ZhenGe Biotechnology, bringing the company’s total financing to $125m.

NatWest Group, Mastercard and National Australia Bank backed the banking software developer's series C round, taking its total funding past $140m.

The Strides-backed protein and peptide-based therapeutics developer has disclosed a $70m series B and $125m C round, valuing it at $350m post-money.

Novartis and Bristol Myers Squibb helped the alpha radiotherapy developer complete a series A round after being incubated by MPM Capital.